Skip to main content
. 2015 Jan 7;6(9):6553–6569. doi: 10.18632/oncotarget.2720

Figure 5. Effects of PF-0477736 in primary lymphoma cells and bone marrow mononucleated cells.

Figure 5

(A) Normal bone marrow mononucleated cells harvested from 7 patients with no signs of bone marrow involvement, at the moment of initial diagnosis, 5 primary indolent B-cell lymphoma samples, and 5 primary aggressive B-cell lymphoma samples were incubated with PF-0477736 500 nM for 24 hours, and cell viability evaluated by trypan-blue staining. The viability of each primary sample was normalized to its own untreated control. Error bars represent s.e.m. BL (Burkitt lymphoma), DLBCL (Diffuse large B-cell lymphoma), CLL (Chronic Lymphocytic Leukemia), HCL (Hairy Cell Leukemia), NBM (Normal bone marrow mononucleated cells), MZL (Marginal zone lymphoma), MCL (Mantle cell lymphoma). (B) Western blot assay showing on treatment modifications of γH2AX and pCHK1 ser 345 in primary cells. Similarly to what we observed in cell lines, treatment with PF-0477736 determined DNA damage accumulation with increased γH2AX and pCHK1 ser 345 levels in DLBCL primary cells, whereas no changes were observed in primary B-CLL cells and normal bone marrow mononucleated cells (NBM). (C) Table showing characteristics of patients whose primary cells were harvested and used for the experiments above.